Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $589.52, for a total transaction of $5,600,440.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,883,223.76. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Trading Down 4.6%

UTHR stock traded down $27.58 during midday trading on Thursday, reaching $569.18. 830,871 shares of the company’s stock traded hands, compared to its average volume of 485,002. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The stock has a market cap of $24.05 billion, a P/E ratio of 20.40, a PEG ratio of 1.63 and a beta of 0.60. The stock’s 50-day moving average is $548.25 and its 200 day moving average is $500.41.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the prior year, the company posted $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on Tyvaso IPF data and the blockbuster potential of ralinepag, which helped shares rally after the Q1 report despite the miss; this pipeline optimism can support longer‑term valuation. Zacks: UTHR Q1 Earnings Miss, Shares Jump on Strong Outlook
• Positive Sentiment: Company highlighted continued clinical progress (including positive ADVANCE O results noted in the press release), which supports revenue growth potential beyond near‑term quarterly fluctuations. BusinessWire: Q1 2026 Financial Results
• Positive Sentiment: Expansion of a DPI/inhaled delivery partnership ecosystem tied to United Therapeutics activity has supportive implications for commercial reach and Tyvaso delivery options. Market reaction to related partnership news lifted peers and signals strategic optionality. Investing.com: MannKind Stock Surges on United Therapeutics Partnership
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly (from $707 to $701) but kept an “outperform” rating — a modest technical downgrade that still implies meaningful upside versus current levels. Benzinga: RBC Lowers Price Target
• Neutral Sentiment: Several analysts have raised targets in recent months (UBS, BofA, Cantor, Oppenheimer), leaving a mixed analyst landscape—some higher targets offset by occasional trims. Investors are parsing these conflicting signals. MarketBeat: UTHR Analyst Coverage
• Negative Sentiment: Q1 results missed estimates: EPS $5.82 vs. consensus near $7.00 and revenue of $781.5M below expectations — a clear near‑term earnings and top‑line disappointment that pressures the stock. Zacks: UTHR Misses Q1 Estimates
• Negative Sentiment: Significant insider sales: CEO and CFO sold multi‑million dollar stakes earlier in the week, which markets often view as a negative signal about near‑term insider conviction. SEC Filing: Insider Sales

Analyst Ratings Changes

A number of brokerages have recently issued reports on UTHR. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. TD Cowen increased their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. HC Wainwright increased their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Wells Fargo & Company set a $735.00 price objective on shares of United Therapeutics and gave the stock an “overweight” rating in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Arjuna Capital grew its holdings in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after buying an additional 18 shares in the last quarter. Clearstead Advisors LLC grew its holdings in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares in the last quarter. Sage Rhino Capital LLC grew its holdings in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC grew its holdings in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares in the last quarter. Finally, Independent Advisor Alliance grew its holdings in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.